Vanda Pharmaceuticals (VNDA) Net Cash Flow (2010 - 2026)

Vanda Pharmaceuticals has reported Net Cash Flow for 17 years, with the latest figure at -$30.8 million in Q1 2026.

• Quarterly Net Cash Flow fell 426.16% year-over-year to -$30.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$57.7 million (down 334.92% YoY) and the FY2025 annual result came in at -$17.5 million, up 47.55% from the prior year.
• Net Cash Flow fell to -$30.8 million in Q1 2026 per VNDA's latest filing, from $14.8 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $219.1 million in Q1 2023 and troughed at -$204.1 million in Q2 2023.
• A 5-year average of $105764.7 and a median of -$8.8 million in 2022 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2023: Net Cash Flow surged 5078.73% in 2022, then plunged 2224.23% in 2023.
• Over 5 years, Net Cash Flow stood at $85.4 million in 2022, then slumped by 155.61% to -$47.5 million in 2023, then surged by 104.25% to $2.0 million in 2024, then jumped by 632.76% to $14.8 million in 2025, then slumped by 307.71% to -$30.8 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$30.8 million, $14.8 million, and -$10.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.